secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001664710-22-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q3 net loss $23.5M; cash runway extended to Q1 2025
---------------------------------------------------------

- Net loss of $23.5M in Q3 2022 vs $20.3M in Q3 2021, driven by higher R&D and G&A costs.
- R&D expenses $21.0M (+$6.2M YoY); G&A expenses $6.9M (+$1.6M YoY).
- Cash and cash equivalents $239.4M at Sep 30, 2022; ATM proceeds extend runway into Q1 2025.
- KER-012 Phase 1 data presented; Phase 2 PAH trial design expected early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/0001664710-22-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000054/kros-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001664710-22-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer